Sticky Protein May Be Responsible For Drug-Resistance Breast Cancer


Sticky protein may be responsible for drug-resistance breast cancer, according to a recent study. Scientists find it difficult to understand why some breast cancers become resistant to drugs.

The hormone estrogen has a key role in the development of breast cancer. According to estimation, 70 percent of all breast cancers are positive to estrogen receptor (ER). Estrogen helps the cancerous cell to grow in the body. The hormone joins estrogen receptors and boosts healthy cell growth that can fuel breast cancer if crossed the defined limit.

Scientists know that estrogen is responsible for the breast cancer, but they failed to find the treatment.

Doctors prescribe drugs to people with an ER-positive form of breast cancer to control it from spreading. But it found that one-third of people diagnosed with endocrine therapy became drug-resistance.

A new study carried out by Rocío Sampayo, a Ph.D. student based at the Instituto de Nanosistemas, Universidad Nacional de San Martin, and Instituto de Oncología “Angel H. Roffo,” Universidad de Buenos Aires — both in Argentina performed an experiment to examine the effect of a glue-like protein called fibronectin.

A new study which states that sticky protein may be responsible for drug-resistance breast cancer was published in the Journal of Cell Biology. It showed that when cancerous cells were exposed to fibronectin, the estrogen receptors’ activity was raised.

The reason for this could be fibronectin. In a normal cell, lysosomes eat estrogen receptors while in breast cancer, fibronectin secures them and promotes their growth.

Sampayo says that drug-resistant breast cancers can be killed by creating a drug affecting the relationship between the protein fibronectin and estrogen receptors.